Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Randomized clinical trial of mast cell inhibition in patients with a medium-sized abdominal aortic aneurysm

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Comment on: Nationwide study of surgery for primary infected abdominal aortic and common iliac artery aneurysms

    Publikation: Bidrag til tidsskriftKommentar/debatForskningpeer review

  2. Secondary effects of the COVID-19 pandemic on surgical management of hepatopancreatobiliary malignancies in the Nordic capitals

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Snapshots Quiz

    Publikation: Bidrag til tidsskriftTidsskriftartikelFormidling

  4. Reporting guideline for interventional trials of primary and incisional ventral hernia repair

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Profiling abdominal aortic aneurysm growth with three-dimensional ultrasound

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Carotid plaque thickness is increased in chronic kidney disease and associated with carotid and coronary calcification

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • H Sillesen
  • N Eldrup
  • R Hultgren
  • J Lindeman
  • K Bredahl
  • M Thompson
  • A Wanhainen
  • U Wingren
  • J Swedenborg
  • AORTA Trial Investigators
Vis graf over relationer

BACKGROUND: Abdominal aortic aneurysm (AAA) is thought to develop as a result of inflammatory processes in the aortic wall. In particular, mast cells are believed to play a central role. The AORTA trial was undertaken to investigate whether the mast cell inhibitor, pemirolast, could retard the growth of medium-sized AAAs. In preclinical and clinical trials, pemirolast has been shown to inhibit antigen-induced allergic reactions.

METHODS: Inclusion criteria for the trial were patients with an AAA of 39-49 mm in diameter on ultrasound imaging. Among exclusion criteria were previous aortic surgery, diabetes mellitus, and severe concomitant disease with a life expectancy of less than 2 years. Included patients were treated with 10, 25 or 40 mg pemirolast, or matching placebo for 52 weeks. The primary endpoint was change in aortic diameter as measured from leading edge adventitia at the anterior wall to leading edge adventitia at the posterior wall in systole. All ultrasound scans were read in a central imaging laboratory.

RESULTS: Some 326 patients (mean age 70·8 years; 88·0 per cent men) were included in the trial. The overall mean growth rate was 2·42 mm during the 12-month study. There was no statistically significant difference in growth between patients receiving placebo and those in the three dose groups of pemirolast. Similarly, there were no differences in adverse events.

CONCLUSION: Treatment with pemirolast did not retard the growth of medium-sized AAAs.

REGISTRATION NUMBER: NCT01354184 (https://www.clinicaltrials.gov).

OriginalsprogEngelsk
TidsskriftThe British journal of surgery
Vol/bind102
Udgave nummer8
Sider (fra-til)894-901
Antal sider8
ISSN0007-1323
DOI
StatusUdgivet - jul. 2015

ID: 45697475